Search
Salmon calcitonin
go.drugbank.com/drugs/DB00017ApprovedInvestigationalSynthetic peptide, 32 residues long formulated as a nasal spray.
Products: Miacalcin Nasal Spray 200 Iu, MIACALCIC INJECTION 50 iu/mlElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].
Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilidePerfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative. … [L46491] It is an inert, slightly amphiphilic compound.
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnAmorolfine or amorolfin, is a morpholine antifungal drug that inhibits the fungal enzymes D14 reductase and D7-D8 isomerase. … It is not approved for the treatment of onychomycosis in the United States or Canada.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
Omidenepag isopropyl
go.drugbank.com/drugs/DB15071ApprovedThe use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.
Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateCategories: Receptors, Prostaglandin E, EP2 Subtype, agonistsPeramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalDue to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalmetastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative